Vitrolife Valuation
| VITR Stock | SEK 212.80 3.00 1.43% |
At this time, the company appears to be overvalued. Vitrolife AB has a current Real Value of kr204.29 per share. The regular price of the company is kr212.8. Our model measures the value of Vitrolife AB from inspecting the company fundamentals such as Operating Margin of 0.20 %, shares outstanding of 135.45 M, and Return On Equity of 0.0246 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vitrolife's price fluctuation is very steady at this time. Calculation of the real value of Vitrolife AB is based on 3 months time horizon. Increasing Vitrolife's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vitrolife's intrinsic value may or may not be the same as its current market price of 212.80, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 212.8 | Real 204.29 | Hype 212.8 | Naive 200.7 |
The intrinsic value of Vitrolife's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vitrolife's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vitrolife AB helps investors to forecast how Vitrolife stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vitrolife more accurately as focusing exclusively on Vitrolife's fundamentals will not take into account other important factors: Vitrolife Total Value Analysis
Vitrolife AB is at this time anticipated to have takeover price of 28.19 B with market capitalization of 31.97 B, debt of 2.03 B, and cash on hands of 630.09 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Vitrolife fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
28.19 B | 31.97 B | 2.03 B | 630.09 M |
Vitrolife Investor Information
About 32.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.61. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vitrolife AB last dividend was issued on the 28th of April 2022. The entity had 5:1 split on the 17th of May 2018. Based on the measurements of operating efficiency obtained from Vitrolife's historical financial statements, Vitrolife AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Vitrolife Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vitrolife has an asset utilization ratio of 8.65 percent. This implies that the Company is making kr0.0865 for each dollar of assets. An increasing asset utilization means that Vitrolife AB is more efficient with each dollar of assets it utilizes for everyday operations.Vitrolife Ownership Allocation
Vitrolife AB shows a total of 135.45 Million outstanding shares. Vitrolife AB maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vitrolife Profitability Analysis
The company reported the revenue of 1.68 B. Net Income was 340.97 M with profit before overhead, payroll, taxes, and interest of 1.78 B.About Vitrolife Valuation
The stock valuation mechanism determines Vitrolife's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vitrolife AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vitrolife. We calculate exposure to Vitrolife's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vitrolife's related companies.Vitrolife AB , a medical device company, develops, produces, and markets products for assisted reproduction. Vitrolife AB was founded in 1981 and is headquartered in Gothenburg, Sweden. Vitrolife operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 415 people.
8 Steps to conduct Vitrolife's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vitrolife's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vitrolife's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vitrolife's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vitrolife's revenue streams: Identify Vitrolife's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vitrolife's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vitrolife's growth potential: Evaluate Vitrolife's management, business model, and growth potential.
- Determine Vitrolife's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vitrolife's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Vitrolife Stock Analysis
When running Vitrolife's price analysis, check to measure Vitrolife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitrolife is operating at the current time. Most of Vitrolife's value examination focuses on studying past and present price action to predict the probability of Vitrolife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitrolife's price. Additionally, you may evaluate how the addition of Vitrolife to your portfolios can decrease your overall portfolio volatility.